Research output per year
Research output per year
Fingerprint
Fingerprints are formed from scientific publications and create an index of weighted keyword concepts for each individual researcher.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Nahi, H., Usmani, S. Z., Mateos, M. V., van de Donk, N. W. C. J., Oriol, A., Plesner, T., Bandyopadhyay, N., Hellemans, P., Tromp, B., Nnane, I., Zemlickis, D., Chari, A. & Moreau, P., 2023, In: Leukemia and Lymphoma. 64, 2, p. 468-472Research output: Contribution to journal › Comment/debate › Research › peer-review
Open AccessFile16 Downloads (Pure) -
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Suzuki, K., Plesner, T., Yoon, S-S., Ben Yehuda, D., Richardson, P. G., Goldschmidt, H., Reece, D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., Carey, J., & 2 others, 10. Mar 2023, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41, 8, p. 1590-1599Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile37 Downloads (Pure) -
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Plesner, T., Harrison, S. J., Quach, H., Lee, C., Bryant, A., Vangsted, A., Estell, J., Delforge, M., Offner, F., Twomey, P., Choeurng, V., Li, J., Hendricks, R., Ruppert, S. M., Sumiyoshi, T., Miller, K., Cho, E. & Schjesvold, F., Mar 2023, In: Clinical Hematology International. 5, p. 43-51Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile7 Downloads (Pure) -
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., Perrot, A., Weisel, K., Raje, N., MacRo, M., Frenzel, L., Leleu, X., Wang, J., Rampelbergh, R. V., Uhlar, C. M., & 4 others, May 2023, In: Future Oncology. 19, 13, p. 887-895Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile9 Downloads (Pure) -
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, T., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., Goldschmidt, H., Quach, H., Mohty, M., Venner, C. P., Weisel, K., Raje, N., Hebraud, B., Belhadj-Merzoug, K., Benboubker, L., Decaux, O., & 8 others, Apr 2022, In: Leukemia. 36, p. 1066-1077Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile21 Downloads (Pure)
Activities
-
Post-ASH 2019
Torben Plesner (Participant)
17. Dec 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
-
American Society of Hematology: 61st Annual Meeting (ASH)
Torben Plesner (Participant)
7. Dec 2019 → 10. Dec 2019Activity: Attending an event › Conference organisation or participation
-
Independent Response Assesment Comittee
Torben Plesner (Participant)
10. Nov 2019 → 12. Nov 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
-
DSMG plenummøde
Torben Plesner (Participant)
6. Nov 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
-
11th European Myeloma Network
Torben Plesner (Participant)
29. Sept 2019 → 30. Sept 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
Press/Media
-
Professor: Medicinrådets afgørelse er chokerende
27/01/2023
1 Media contribution
Press/Media: Press / Media
-
Professor: Medicinrådets afgørelse giver kun mening, hvis man anskuer processen som en gidselaktion
27/01/2023
1 Media contribution
Press/Media: Press / Media
-
Professor: Medicinrådets afgørelse er et kæmpe tab for patienter med knoglemarvskræft
27/01/2023
1 Media contribution
Press/Media: Press / Media
-
Det bliver mere og mere farligt at være en kræftcelle ved knoglemarvskræft
24/10/2022
1 Media contribution
Press/Media: Press / Media
-
Det bliver mere og mere farligt at være kræftcelle ved knoglemarvskræft
14/10/2022
1 Media contribution
Press/Media: Press / Media
Prizes
-
Ekstern bevilling: Oncopeptides kr. 50.000
Plesner, Torben (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: Celgene kr. 428.987
Plesner, Torben (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: Roche kr. 254.017
Plesner, Torben (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: BMS kr. 464.022
Plesner, Torben (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: Genmab kr. 834.855
Plesner, Torben (Recipient), 2013
Prize: Prizes, scholarships, distinctions